Editas Medicine Company Profile (NASDAQ:EDIT)

About Editas Medicine (NASDAQ:EDIT)

Editas Medicine logoEditas Medicine, Inc. is a genome editing company. It is engaged in treating patients with genetically defined diseases by correcting their disease-causing genes. It operates through developing and commercializing genome editing technology segment. It is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR) technology. CRISPR uses a protein-ribonucleic acid (RNA) complex composed of an enzyme, including either CRISPR associated protein 9 (Cas9) or CRISPR from Prevotella and Francisella 1 (Cpf1), bound to a guide RNA molecule designed to recognize a particular deoxyribonucleic acid (DNA) sequence. Its platform consists of four components: nuclease engineering, delivery, control and specificity, and directed editing. Its programs include Eye Diseases, Engineered T Cell Therapies for Immuno-Oncology and additional research programs. It is developing a genome editing therapeutic for Leber Congenital Amaurosis type 10 (LCA10).

Industry, Sector and Symbol: Capitalization:
  • Market Cap: $704.61 million
  • Outstanding Shares: 40,729,000
Average Prices:
  • 50 Day Moving Avg: $19.57
  • 200 Day Moving Avg: $19.03
  • 52 Week Range: $12.43 - $38.25
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -6.53
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $5.93 million
  • Price / Sales: 118.82
  • Book Value: $5.07 per share
  • Price / Book: 3.41
Profitability:
  • EBIDTA: ($108,330,000.00)
  • Net Margins: -1,184.46%
  • Return on Equity: -59.22%
  • Return on Assets: -31.66%
Debt:
  • Debt-to-Equity Ratio: 0.19%
  • Current Ratio: 14.80%
  • Quick Ratio: 14.80%
Misc:
  • Average Volume: 894,527 shs.
  • Short Ratio: 3.78
 

Frequently Asked Questions for Editas Medicine (NASDAQ:EDIT)

What is Editas Medicine's stock symbol?

Editas Medicine trades on the NASDAQ under the ticker symbol "EDIT."

How were Editas Medicine's earnings last quarter?

Editas Medicine Inc (NASDAQ:EDIT) posted its quarterly earnings data on Monday, May, 15th. The company reported ($0.85) EPS for the quarter, missing the Zacks' consensus estimate of ($0.62) by $0.23. The business earned $0.68 million during the quarter, compared to analysts' expectations of $1 million. Editas Medicine had a negative net margin of 1,184.46% and a negative return on equity of 59.22%. The firm's quarterly revenue was down 16.0% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.80) earnings per share. View Editas Medicine's Earnings History.

Where is Editas Medicine's stock going? Where will Editas Medicine's stock price be in 2017?

4 brokers have issued 1 year price objectives for Editas Medicine's stock. Their forecasts range from $32.00 to $35.00. On average, they anticipate Editas Medicine's stock price to reach $33.50 in the next twelve months. View Analyst Ratings for Editas Medicine.

What are analysts saying about Editas Medicine stock?

Here are some recent quotes from research analysts about Editas Medicine stock:

  • 1. According to Zacks Investment Research, "Editas Medicine, Inc. is a genome editing company. It focuses on translating its genome editing technology into a novel class of human therapeutics which enable precise and corrective molecular modification to treat diseases. Editas Medicine, Inc. is based in Cambridge, Massachusetts. " (3/28/2017)
  • 2. Chardan Capital analysts commented, "We initiate coverage of Editas Medicine (EDIT) with a Buy rating (PT $65), on our view of the company's IP breadth and strength providing significant upside potential for shares, via both internal and partnered program opportunities. Editas is a preclinical biotech company aiming to treat various genetic conditions through the CRISPR gene editing system, in which a CRISPR guide RNA (gRNA) delivers a nuclease (a sort of "DNA scissors") to specifically modify a particular DNA sequence to treat diseases. Editas' lead asset, targeting Leber's congenital amaurosis type 10 (LCA10), could be one of the first CRISPR therapies to enter the clinic. An IND filing is expected by year-end 2017." (3/27/2017)
  • 3. Cowen and Company analysts commented, "Today Editas partnered its ophthalmology CRISPR programs with Allergan for $90MM." (3/15/2017)
  • 4. Jefferies Group LLC analysts commented, "We gained incremental color on IP and pipeline progress from our meeting. Mgmt continues to be confident about their broad IP portfolio, which allows them to be prepared for any possible outcome from ongoing interference proceedings. The LCA10 IND filing remains on track by YE17 and likely would require a RAC meeting. Mgmt laid out key elements for the IND filing package and expect to present NHP data at medical meetings in 2017." (2/15/2017)

Who are some of Editas Medicine's key competitors?

When did Editas Medicine IPO?

(EDIT) raised $100 million in an initial public offering (IPO) on Wednesday, February 3rd 2016. The company issued 5,900,000 shares at $16.00-$18.00 per share. Morgan Stanley and J.P. Morgan served as the underwriters for the IPO and Cowen and Company and JMP Securities were co-managers.

Who owns Editas Medicine stock?

Editas Medicine's stock is owned by a number of of institutional and retail investors. Top institutional investors include FMR LLC (16.47%), Polaris Venture Management Co. VI L.L.C. (10.59%), Flagship Pioneering Inc. (9.42%), Vanguard Group Inc. (5.40%), Clough Capital Partners L P (1.09%) and Morgan Stanley (0.86%). Company insiders that own Editas Medicine stock include Alexandra Glucksmann, Andrew A F Hack, James E Flynn, Kevin Bitterman, Kevin P Starr and Polaris Venture Management Co. View Institutional Ownership Trends for Editas Medicine.

Who sold Editas Medicine stock? Who is selling Editas Medicine stock?

Editas Medicine's stock was sold by a variety of institutional investors in the last quarter, including Flagship Pioneering Inc., Credit Suisse AG, ProShare Advisors LLC and TIAA CREF Investment Management LLC. Company insiders that have sold Editas Medicine stock in the last year include Alexandra Glucksmann, Andrew A F Hack, Kevin Bitterman, Kevin P Starr and Polaris Venture Management Co. View Insider Buying and Selling for Editas Medicine.

Who bought Editas Medicine stock? Who is buying Editas Medicine stock?

Editas Medicine's stock was purchased by a variety of institutional investors in the last quarter, including Vanguard Group Inc., FMR LLC, Clough Capital Partners L P, LMR Partners LLP, York Capital Management Global Advisors LLC, Morgan Stanley, Driehaus Capital Management LLC and UBS Group AG. View Insider Buying and Selling for Editas Medicine.

How do I buy Editas Medicine stock?

Shares of Editas Medicine can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Editas Medicine stock cost?

One share of Editas Medicine stock can currently be purchased for approximately $17.30.

Analyst Ratings

Consensus Ratings for Editas Medicine (NASDAQ:EDIT) (?)
Ratings Breakdown: 1 Hold Rating, 3 Buy Ratings
Consensus Rating:Buy (Score: 2.75)
Consensus Price Target: $33.50 (93.64% upside)

Analysts' Ratings History for Editas Medicine (NASDAQ:EDIT)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
3/27/2017Chardan CapitalInitiated CoverageBuy -> BuyHighView Rating Details
3/15/2017Cowen and CompanyReiterated RatingBuyLowView Rating Details
3/8/2017JPMorgan Chase & Co.Set Price TargetHold$32.00LowView Rating Details
2/15/2017Jefferies Group LLCReiterated RatingBuy$35.00N/AView Rating Details
2/29/2016Morgan StanleyInitiated CoverageEqual -> Equal Weight$28.00N/AView Rating Details
2/29/2016JMP SecuritiesInitiated CoverageOutperform$40.00N/AView Rating Details
(Data available from 5/23/2015 forward)

Earnings

Earnings History for Editas Medicine (NASDAQ:EDIT)
Earnings by Quarter for Editas Medicine (NASDAQ:EDIT)
Earnings History by Quarter for Editas Medicine (NASDAQ:EDIT)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/15/2017Q1 2017($0.62)($0.85)$1.00 million$0.68 millionViewN/AView Earnings Details
3/7/2017Q4 2016($0.62)($1.10)$1.11 million$0.90 millionViewListenView Earnings Details
11/7/2016Q3($0.64)($0.59)$1.00 million$1.00 millionViewListenView Earnings Details
8/9/2016Q2($0.54)($0.54)$3.52 million$3.39 millionViewListenView Earnings Details
5/16/2016Q116($0.23)($0.80)$1.08 million$0.80 millionViewListenView Earnings Details
3/30/2016Q4($0.52)($4.05)$0.79 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Editas Medicine (NASDAQ:EDIT)
2017 EPS Consensus Estimate: ($2.86)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.66)($0.66)($0.66)
Q2 20171($0.70)($0.70)($0.70)
Q3 20171($0.73)($0.73)($0.73)
Q4 20171($0.77)($0.77)($0.77)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Editas Medicine (NASDAQ:EDIT)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Editas Medicine (NASDAQ:EDIT)
Institutional Ownership Percentage: 60.89%
Insider Trades by Quarter for Editas Medicine (NASDAQ:EDIT)
Institutional Ownership by Quarter for Editas Medicine (NASDAQ:EDIT)
Insider Trades by Quarter for Editas Medicine (NASDAQ:EDIT)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
3/15/2017Alexandra GlucksmannCOOSell1,000$26.41$26,410.00View SEC Filing  
2/15/2017Alexandra GlucksmannCOOSell6,000$20.58$123,480.00View SEC Filing  
2/15/2017Andrew A F HackCFOSell3,000$19.20$57,600.00View SEC Filing  
1/11/2017Andrew A F HackCFOSell15,000$19.20$288,000.00View SEC Filing  
12/7/2016Polaris Venture Management Co.Major ShareholderSell75,000$15.82$1,186,500.00View SEC Filing  
12/6/2016Kevin BittermanDirectorSell130,000$15.79$2,052,700.00View SEC Filing  
11/23/2016Kevin BittermanDirectorSell21,480$15.71$337,450.80View SEC Filing  
11/22/2016Polaris Venture Management Co.Major ShareholderSell12,819$15.77$202,155.63View SEC Filing  
11/15/2016Kevin BittermanDirectorSell88,900$16.96$1,507,744.00View SEC Filing  
9/8/2016Polaris Venture Management Co.Major ShareholderSell500,000$16.80$8,400,000.00View SEC Filing  
9/6/2016Kevin P. StarrMajor ShareholderSell5,890$15.90$93,651.00View SEC Filing  
8/23/2016Alexandra GlucksmannCOOSell1,000$20.00$20,000.00View SEC Filing  
2/8/2016James E FlynnInsiderBuy100,000$16.00$1,600,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Editas Medicine (NASDAQ:EDIT)
Latest Headlines for Editas Medicine (NASDAQ:EDIT)
Source:
DateHeadline
americanbankingnews.com logoEditas Medicine Inc (EDIT) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - May 19 at 2:02 PM
nasdaq.com logoEditas Medicine Announces First Quarter 2017 Results and Update ... - Nasdaq
www.nasdaq.com - May 16 at 4:51 PM
rttnews.com logoEditas Medicine Inc. (EDIT) Is Falling After Q1 Loss Widens
www.rttnews.com - May 16 at 11:57 AM
finance.yahoo.com logoEditas reports 1Q loss
finance.yahoo.com - May 16 at 11:57 AM
finance.yahoo.com logoEdited Transcript of EDIT earnings conference call or presentation 15-May-17 9:00pm GMT
finance.yahoo.com - May 16 at 11:57 AM
americanbankingnews.com logoEditas Medicine Inc (EDIT) Posts Earnings Results, Misses Estimates By $0.14 EPS
www.americanbankingnews.com - May 15 at 9:20 PM
reuters.com logoBRIEF-Editas Medicine Q1 loss per share $0.85
www.reuters.com - May 15 at 4:40 PM
finance.yahoo.com logoInvestor Network: Editas Medicine, Inc. to Host Earnings Call
finance.yahoo.com - May 15 at 4:40 PM
finance.yahoo.com logoEditas Medicine Announces First Quarter 2017 Results and Update
finance.yahoo.com - May 15 at 4:40 PM
nasdaq.com logoWhy Editas Medicine (EDIT) Might Surprise This Earnings Season - Nasdaq
www.nasdaq.com - May 14 at 9:18 AM
globenewswire.com logoEditas Medicine Demonstrates First Achievement of In Vivo Editing in Non-human Primate Retinas - GlobeNewswire (press release)
www.globenewswire.com - May 14 at 9:18 AM
finance.yahoo.com logoEditas Medicine Demonstrates First Achievement of In Vivo Editing in Non-human Primate Retinas
finance.yahoo.com - May 13 at 4:48 PM
bizjournals.com logoHow Alphabet's venture arm is fueling the Mass. life science cluster
www.bizjournals.com - May 12 at 5:21 PM
finance.yahoo.com logoWhy Editas Medicine (EDIT) Might Surprise This Earnings Season
finance.yahoo.com - May 12 at 5:21 PM
nasdaq.com logoEditas Medicine Announces Pre-Clinical Data for Program to Treat Sickle Cell Disease and Beta-Thalassemia - Nasdaq
www.nasdaq.com - May 11 at 10:32 PM
finance.yahoo.com logoEditas Medicine Announces Pre-Clinical Data for Program to Treat Sickle Cell Disease and Beta-Thalassemia
finance.yahoo.com - May 11 at 5:31 PM
globenewswire.com logoEditas Medicine to Present at Investor Conferences in May - GlobeNewswire (press release)
globenewswire.com - May 9 at 7:32 AM
finance.yahoo.com logoEditas Medicine to Host Conference Call Discussing First Quarter 2017 Corporate Update and Results
finance.yahoo.com - May 8 at 4:46 PM
finance.yahoo.com logoEditas Medicine to Present at Investor Conferences in May
finance.yahoo.com - May 8 at 4:46 PM
nasdaq.com logoCan Ligand (LGND) Spring a Surprise this Earnings Season?
www.nasdaq.com - May 4 at 11:43 AM
finance.yahoo.com logoCEOs of top gene-editing firms got huge compensation hikes last year
finance.yahoo.com - April 27 at 5:26 PM
finance.yahoo.com logoToday's Bell Ringer, April 25, 2017
finance.yahoo.com - April 25 at 11:39 AM
streetinsider.com logoEditas Medicine (EDIT) to Present New Data Showing Advancements for Translating CRISPR Technologies into Medicines at ASGCT
www.streetinsider.com - April 24 at 4:45 PM
finance.yahoo.com logoEditas Medicine, Inc. (Nasdaq: EDIT) to Ring The Nasdaq Stock Market Opening Bell
finance.yahoo.com - April 24 at 4:45 PM
americanbankingnews.com logoEditas Medicine Inc (EDIT) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - April 24 at 1:54 PM
americanbankingnews.com logo$1.08 Million in Sales Expected for Editas Medicine Inc (EDIT) This Quarter
www.americanbankingnews.com - April 22 at 8:11 AM
americanbankingnews.com logoZacks: Analysts Anticipate Editas Medicine Inc (EDIT) to Post -$0.63 EPS
www.americanbankingnews.com - April 20 at 6:05 PM
finance.yahoo.com logoEditas foes add legal firepower as gene-editing case goes to appeal
finance.yahoo.com - April 13 at 4:50 PM
americanbankingnews.com logoEditas Medicine Inc (EDIT) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - April 4 at 9:17 AM
americanbankingnews.com logoZacks Investment Research Upgrades Editas Medicine Inc (EDIT) to Hold
www.americanbankingnews.com - April 3 at 8:50 AM
biz.yahoo.com logoEDITAS MEDICINE, INC. Files SEC form 8-K, Creation of a Direct Financial Obligation or an Obligation under an Off-Bal
biz.yahoo.com - March 31 at 4:59 PM
bizjournals.com logoNew Cambridge biotech Tango aims to make cancer its own worst enemy
www.bizjournals.com - March 30 at 5:20 PM
americanbankingnews.com logoZacks Investment Research Upgrades Editas Medicine Inc (EDIT) to "Hold"
www.americanbankingnews.com - March 28 at 7:28 PM
finance.yahoo.com logoCoverage initiated on Editas Medicine by Chardan Capital Markets
finance.yahoo.com - March 28 at 12:03 PM
americanbankingnews.com logoEditas Medicine Inc (EDIT) Coverage Initiated by Analysts at Chardan Capital
www.americanbankingnews.com - March 27 at 6:27 PM
americanbankingnews.com logoVetr Inc. Upgrades Editas Medicine Inc (EDIT) to "Strong-Buy"
www.americanbankingnews.com - March 26 at 12:04 AM
americanbankingnews.com logoEditas Medicine Inc (EDIT) Upgraded to Strong-Buy at Vetr Inc.
www.americanbankingnews.com - March 24 at 7:20 AM
finance.yahoo.com logoEditas Get A Vetr Upgrade To Strong Buy
finance.yahoo.com - March 21 at 8:21 AM
biz.yahoo.com logoEDITAS MEDICINE, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial Stateme
biz.yahoo.com - March 17 at 5:11 PM
reuters.com logoBRIEF-Editas announces pricing of $90 million offering of common stock
www.reuters.com - March 16 at 11:17 PM
finance.yahoo.com logoEditas Medicine, Inc. Announces Pricing of $90 Million Offering of Common Stock
finance.yahoo.com - March 16 at 11:17 PM
bizjournals.com logoPig organs in humans? George Church-founded biotech banks $38M to try
www.bizjournals.com - March 16 at 3:21 AM
zacks.com logoAllergan (AGN) and Editas Tie Up to Treat Eye Diseases
www.zacks.com - March 15 at 5:17 PM
reuters.com logoBRIEF-Editas medicine announces proposed offering of common stock
www.reuters.com - March 15 at 5:17 PM
biz.yahoo.com logoEDITAS MEDICINE, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement
us.rd.yahoo.com - March 15 at 5:17 PM
us.rd.yahoo.com logoEditas Medicine, Inc., Announces Proposed Offering of Common Stock
us.rd.yahoo.com - March 15 at 5:17 PM
nasdaq.com logoFDA Panel Snubs ENDP, Watch Out For TCON, MRK's Keytruda Scores Another Win
www.nasdaq.com - March 15 at 2:20 AM
News IconUPDATE 1-Allergan signs deal with Editas for gene-editing-based eye treatments
www.businessinsider.com - March 15 at 2:20 AM
nasdaq.com logoEditas Medicine Inc. (EDIT) Is Up Sharply After Allergan Alliance - Nasdaq
www.nasdaq.com - March 14 at 4:17 PM
biz.yahoo.com logoAllergan plc and Editas Medicine Inc Enter into Strategic R&D Alliance to Discover and Develop CRISPR Genome Editing Medicines for Eye Diseases Call scheduled for 4:30 pm ET today
biz.yahoo.com - March 14 at 4:17 PM

Social

Chart

Editas Medicine (EDIT) Chart for Tuesday, May, 23, 2017

This page was last updated on 5/23/2017 by MarketBeat.com Staff